SCTbio is a cell therapy and retrovirus vector CDMO spun off from the SOTIO group in 2021, led by a close-knit team that has completed all stages of process and product development over the last decade, bringing Sotio Biotech’s autologous cell therapies into Phase III. From its 2,000 m² facility in Central Europe, SCTbio offers personalized attention through long-term manufacturing partnerships, strategic development and regulatory advice, as well as comprehensive services covering GMP production, testing and logistics for advanced therapy medical products, including genetically modified and viral vectors.
SCTbio is supported by the PPF group.
